Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thirty years of hepatitis A epidemiology and vaccine studies: A narrative review of lessons learned in Alaska.

Annals of epidemiology·2026
Same author

Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B?

Expert review of anticancer therapy·2026
Same author

Elimination of Hepatitis B virus transmission in an endemic area in Western Alaska.

IJID regions·2025
Same author

Modeling 5-Year Hepatocellular Carcinoma Risk in Alaska Native Peoples With Hepatitis B Virus Infection.

Gastro hep advances·2025
Same author

HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening.

Hepatology communications·2025
Same author

Hepatitis B Care and Treatment in Zanzibar, Tanzania: A Demonstration Project Following 2015 WHO Treatment Guidelines, 2017-2021.

Journal of viral hepatitis·2024
Same journal

Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?

F1000 medicine reports·2013
Same journal

Advances in lens implant technology.

F1000 medicine reports·2013
Same journal

Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population.

F1000 medicine reports·2013
Same journal

Cannabis and psychosis: what causes what?

F1000 medicine reports·2013
Same journal

Prevention of atopic dermatitis.

F1000 medicine reports·2012
Same journal

Lung inflammation in COPD: why does it matter?

F1000 medicine reports·2012
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Recent advances in managing hepatitis B.

Brian J McMahon1

  • 1Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium 4315 Diplomacy Drive, Anchorage, AK 99508 USA.

F1000 Medicine Reports
|October 16, 2010
PubMed
Summary
This summary is machine-generated.

Updated hepatitis B guidelines now include new screening recommendations and first-line antiviral treatments. This review covers management of hepatitis B and HIV co-infection and screening for immunosuppressive therapy.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 8, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Recent updates from national and international bodies have revised practice guidelines for hepatitis B.
  • New antiviral medications have become available for hepatitis B treatment.
  • Co-infection with human immunodeficiency virus (HIV) and the need for screening in immunosuppressed individuals are key considerations.

Purpose of the Study:

  • To review updated recommendations for hepatitis B screening.
  • To discuss first-line antiviral medications for hepatitis B treatment.
  • To outline recent guidelines for managing hepatitis B/HIV co-infection and screening in immunosuppressed patients.

Main Methods:

  • Literature review of recent national and international guidelines.
  • Analysis of newly available antiviral therapies for hepatitis B.
  • Synthesis of recommendations for specific patient populations.

Main Results:

  • New guidelines provide updated criteria for hepatitis B screening.
  • Specific first-line antiviral agents are recommended for treatment initiation.
  • Clear protocols exist for managing hepatitis B/HIV co-infection and screening in immunosuppressed individuals.

Conclusions:

  • Adherence to updated guidelines is crucial for effective hepatitis B management.
  • Newer antiviral drugs offer improved treatment options.
  • Proactive screening and management are essential for co-infected and immunosuppressed patients.